By Josh Beckerman
Neuphoria Therapeutics shares closed up in their first Nasdaq trading day after Bionomics re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics.
The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session.
The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 24, 2024 13:49 ET (18:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.